Clinical Neuropharmacology
September 1, 2025
Jaime Moreno‐chaparro, Gabriela Castañeda-millán, Javier Eslava‐schmalbach
3 citations
Objective: Due to the boom in the use of certain psychedelics in different neuropsychiatric conditions, the objective was to synthesize the available information on the use of psilocybin (a psychedelic) in the population with autism spectrum disorder (ASD; a developmental neuropsychiatric condition). Methods: Scoping review. Question framework: Population: people with ASD—Concept:...
Psychedelics
August 26, 2025
Harriet de Wit
Professor Harriet de Wit, a pioneering researcher in psychoactive drugs at the University of Chicago, shares her remarkable 45-year scientific journey in this illuminating Genomic Press Interview. As Director of the Human Behavioral Pharmacology Laboratory and recipient of prestigious honors including the 2019 European Behavioral Pharmacology Society Distinguished Investigator Award, Dr. de Wit...
Research Square
August 22, 2025
Richard J. Zeifman, George Danias, Gabrielle Agin-Liebes et al.
2 citations
preprint
Abstract Background: Psychedelics can acutely induce mystical experiences and elevated positive mood, which may contribute to the potential benefits of psychedelic therapy. However, there remains limited understanding of the occurrence and importance of specific positive emotional experiences within psychedelic therapy. Therefore, we examined the effects of psychedelics on positive emotional...
The International Journal of Neuropsychopharmacology
August 1, 2025
Thibault Renoir, James J Gattuso, Bilgenur Bezcioglu et al.
Abstract Background The evident limitations of current treatments for depression, anxiety and obsessive-compulsive disorder (OCD), underscore the need for a paradigm shift in how we understand and treat these disorders. There is enormous public and research enthusiasm for the potential that psychedelic drugs like psilocybin, the psychoactive compound produced by “magic mushrooms” will drive a...
Preventive Medicine Reports
August 1, 2025
Pedro J. Teixeira, Rakesh Jain, Andrew Penn et al.
1 citation
Psychedelics have been increasingly studied for their potential to influence mental health and well-being, yet their relationship with broader health behaviors remains underexplored. This study examined associations between lifetime psychedelic use and health-related behaviors, including substance use, dietary habits, and impulsive tendencies. Using an extensive cross-sectional online survey,...
Journal of Eating Disorders
July 24, 2025
Sarah-Catherine Rodan, Noah Meez, Sophie Lloyd-Hurwitz et al.
2 citations
There are few effective treatments for eating disorders (EDs), and new interventions are urgently needed. The MEDication and other drugs For Eating Disorders ("MED-FED") survey investigated the lived experience of adults with EDs regarding their prescription and non-prescription drugs use. Psychedelic drugs were highly rated in this survey for their impact on ED symptoms and general mental...
Neuropsychopharmacology
July 15, 2025
Maria Beatriz Bistue Millón, Laura Noguera, Diana Bruno et al.
4 citations
This Phase I clinical trial is the first to rigorously evaluate the safety, tolerability, and pharmacokinetics of a novel sublingual formulation of 5-MeO-DMT, administered at sub-psychedelic doses to adults with moderate to high levels of anxiety and/or depression, without formal psychiatric diagnosis or ongoing treatment. Using a double-blind, placebo-controlled design, participants received a...
CNS Drugs
July 10, 2025
Eric A. Miller, Christy Capone, Erica Eaton et al.
4 citations
Psychedelics have been studied since the 1950s as a potential treatment for alcohol use disorder (AUD), with over a dozen clinical trials of lysergic acid diethylamide (LSD), and several contemporary trials of psilocybin and ayahuasca for this indication. Herein, we characterize foundational studies from the 1950s to the present, with emphasis on key design factors that varied considerably...
Journal of Homosexuality
July 8, 2025
Riccardo Miceli Mcmillan, James A Fowler, Tamara C. Erbacher et al.
2 citations
Psychedelic-Assisted Therapy (PAT) is a rapidly growing therapeutic approach that to date has rarely considered the nuanced needs of LGBTQA+ individuals. This study explores what LGBTQA+ individuals consider important for healthcare providers (HCPs) to consider when providing PAT. A global sample of LGBTQA+ individuals aged 18+ who had experience using a classic psychedelic compound at least...
bioRxiv : the preprint server for biology
June 15, 2025
Michael Von Gunten, Tenna Russell, Isaac Stirland et al.
preprint
Psychedelics are emerging as a promising treatment option for a range of neuropsychiatric disorders, including substance use disorders. One potential mechanism underlying their therapeutic benefits may involve a reversal of maladaptive plasticity induced by drug exposure. Here, we identify physiological, behavioral, and epigenetic impacts of lysergic acid diethylamide (LSD) on morphine-treated...